Evidence map›Paper›PMID 16537673›Full record

ArticleJournal of clinical pathology2006

Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer.

M Branca, C Giorgi, M Ciotti, D Santini, L Di Bonito, S Costa, A Benedetto, D Bonifacio, P Di Bonito, P Paba and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.Laboratory investigation; a journal of technical methods and pathology · 2018
    Article
  2. Regulation of the metastasis suppressor Nm23-H1 by tumor viruses.Naunyn-Schmiedeberg's archives of pharmacology · 2015
    Review
  3. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2012
    Article
  4. Article
  5. Article
  6. Clinical-translational approaches to the Nm23-H1 metastasis suppressor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

M BrancaUnità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità (ISS), Rome, Italy.
C Giorgi
M Ciotti
D Santini
L Di Bonito
S Costa
A Benedetto
D Bonifacio
P Di Bonito
P Paba
L Accardi
L Mariani
M Ruutu
C Favalli
K Syrjänen
HPV-Pathogen Istituto Superiore di Sanità Study Group
Policlinico Tor Vergata · ITOspedale Maggiore · ITIstituti Fisioterapici Ospitalieri · ITIstituto Superiore di Sanità · ITTurku University Hospital · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOne of the factors leading to an invasive phenotype is the nm23 family of metastases-associated genes. Of the six known members, nm23-H1 is the most frequently studied potential anti-metastatic gene in cervical cancer. However, the possible molecular links to oncogenic human papillomavirus (HPV) are completely unexplored as yet. MATERIALS AND

methodsAs a part of the HPV-Pathogen Istituto Superiore di Sanità study, a series of 150 squamous cell carcinomas (SCCs) and 152 cervical intraepithelial neoplasia (CIN) lesions were examined by immunohistochemical staining for nm23-H1, and tested for HPV by polymerase chain reaction (PCR) with three sets of primers (MY09/11, GP5(+)/GP6(+) and short PCR fragment). Follow-up data were available on all patients with SCC, and 67 CIN lesions were monitored by serial PCR for clearance or persistence of HPV after cone treatment.

resultsA linear decrease (p = 0.001) was observed in nm23-H1 expression, starting from CIN1 (85% with normal expression), with the most dramatic down regulation on transition from CIN2 (70% normal) to CIN3 (39%) and further to SCC (25%). Reduced expression was associated with CIN3 or cancer at an odds ratio 8.72 (95% confidence interval 4.13 to 18.41). Nm23-H1 was of no use as a marker of the high-risk human papillomavirus (HR-HPV) type, and it did not predict clearance or persistence of HR-HPV after treatment of CIN. Importantly, nm23-H1 expression was a significant prognostic factor in cervical cancer, reduced expression being associated with lower survival (p = 0.022) in univariate analysis. In the multivariate (Cox) regression model, however, only the International Federation of Gynecology and Obstetrics stage (p = 0.001) and age (p = 0.011) remained independent prognostic predictors.

conclusionsDown-regulated nm23-H1 expression is markedly associated with progression from CIN2 to CIN3, and predicts poor prognosis in cervical cancer. Nm23-H1 down regulation is probably orchestrated by mechanisms independent of HR-HPV oncoproteins and is possibly related to the emergence of a proteolytic phenotype.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellDisease ProgressionDown-RegulationEpidemiologic MethodsFemaleHumansMiddle AgedNucleoside-Diphosphate KinasePapillomaviridaePapillomavirus InfectionsPolymerase Chain ReactionBiomarkers, TumorNucleoside-Diphosphate Kinase

Identifiers

PMID16537673
PMCPMC1861749
OpenAlexW2161673723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.